Head and Neck Cancer News
This study assessed causes of early mortality stratified by HPV status in oropharynx cancer.
Overall, 87.4 percent of 239 patients achieved negative margins with endoscopic resection.
Authors recommend pembrolizumab, with or without chemotherapy, as first-line treatment.
Findings show that survival declines, recurrence increases with delays of more than 60 days.
Researchers determined the 5-year overall and disease-free survival for patients with CSCC of the head and neck who received adjuvant radiation therapy.
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Nasogastric tubes placed reactively or gastrostomy tubes placed prophylactically? Head and neck cancer experts weigh in on which they, and their patients, prefer to use.
Receiving cancer treatment at a non–National Cancer Institute-designated Comprehensive Cancer Center was associated with higher drug cost, a cohort study found.
Risk for head, neck melanoma higher for male sex, older age, non-Hispanic white ethnicity
From 2013 to 2014, incidence of HPV-positive oropharyngeal cancers was 4.62 per 100,000 persons.
Benefit not significant for aspirin use in patients with non-small cell lung cancer undergoing SBRT.
Four distinct immunologic groups independent of patient age were identified and correlated with overall survival in patients with high-grade glioma.
Patients with higher dysphagia scores also experienced worse febrile neutropenia and diarrhea.
Patients with HPV–associated oropharyngeal squamous cell carcinoma who adhered to the NCCN clinical surveillance recommendations did have improved survival.
Education level, insurance type also may affect likelihood of oral cancer screening at dental visit.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
Incidence was greatest among white men aged 60 to 64 years.
Elimination of radiation therapy did not alter quality-of-life outcomes.
Age was not a significant prognostic factor for long-term survival after transthoracic esophagectomy among patients with thoracic esophageal cancer.